Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT03286114
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    200mg IV every 21 days

Study Details

This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopoetic stem cell transplant.

Key Dates

Start date
Dec 21, 2017
Status verified
Apr 2025
Primary completion
Oct 22, 2020
Completion
Apr 28, 2021

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab

Primary Outcome Measure

The Number of Patients That Demonstrate Clinical Benefit From Treatment [ Time Frame: Day 77 ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Cancer CenterAnn ArborMichigan48109-

Related coverage on Hipa.ai

Find similar trials in Ann Arbor, MI

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
University of Michigan Cancer Center· Ann Arbor, MI

Related Studies